MacroGenics Inc (MGNX) Drops 6.09% on January 27

Equities Staff |

MacroGenics Inc (MGNX) was one of the Russell 2000's biggest losers for Wednesday January 27 as the stock slid 6.09% to $20.80, a loss of $-1.35 per share. Starting at an opening price of $22.15 a share, the stock traded between $20.77 and $22.33 over the course of the trading day. Volume was 119,807 shares over 1,680 trades, against an average daily volume of 323,955 shares and a total float of 34.31 million.

The losses send MacroGenics Inc down to a market cap of $713.7 million. In the last year, MacroGenics Inc has traded between $39.90 and $19.67, and its 50-day SMA is currently $29.71 and 200-day SMA is $30.89.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases.

MacroGenics Inc is based out of Rockville, MD and has some 211 employees. Its CEO is Scott Koenig.

For a complete fundamental analysis analysis of MacroGenics Inc, check out’s Stock Valuation Analysis report for MGNX. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Relevium Technologies Inc.

Relevium Technologies Inc is engaged in the acquisition of products, technologies and businesses relating to musculoskeletal function, specifically Pain Relief, Injury Recovery and Active Performance.

Private Markets


The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…


Autonomous security robots providing advanced detection capabilities at $7 per hour - aiming to define the future of security. Help #StopTheViolence.